On-treatment dNLR and metastatic burden predict survival in advanced non-small-cell lung cancer treated with nivolumab
Turkish Journal of Clinics and Laboratory · 28.03.2026 · (1)
DOI: 10.18663/tjcl.1849630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Clinics and Laboratory, online erschienen am 28.03.2026. Verfasst von Tolga Doğan und 10 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Gefördert von: This study did not receive any financial support from public, commercial, or non-profit funding agencies..
Abstract (Originalsprache)
Aim
Despite the survival benefit achieved with immune checkpoint inhibitors in advanced non–small-cell lung cancer (NSCLC), outcomes remain heterogeneous. While PD-L1 expression is an established biomarker, less is known about the prognostic relevance of on-treatment systemic inflammatory dynamics and the utility of endothelial stress–based indices such as the Endothelial Activation and Stress Index (EASIX) in patients receiving immunotherapy.Material and Methods: We retrospectively evaluated patients with advanced NSCLC treated with nivolumab. PD-L1 expression, metastatic burden, baseline inflammatory parameters, and baseline EASIX were recorded. On-treatment inflammatory markers, including derived neutrophil-to-lymphocyte ratio (dNLR) at 3 months and longitudinal changes in NLR (ΔNLR), were analyzed. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan–Meier and Cox regression models. To account for time-dependent bias, 3-month landmark analyses were performed.
Results
Eighty-one patients were included. High PD-L1 expression (≥50%) was associated with significantly improved OS but did not retain independent prognostic significance for PFS. A high metastatic burden, particularly involvement of four or more metastatic organs, was associated with inferior OS. In landmark-adjusted analyses, dNLR at 3 months was independently associated with both OS and PFS, while ΔNLR was associated with OS, indicating that favorable on-treatment immune–inflammatory changes correlated with improved survival. Baseline EASIX was not associated with either OS or PFS.
Conclusion
In nivolumab-treated advanced NSCLC, survival outcomes are primarily driven by tumor biology, disease burden, and immune–inflammatory dynamics evolving during therapy. On-treatment inflammatory markers, particularly dNLR and ΔNLR, provide more clinically relevant prognostic information than baseline indices, whereas baseline EASIX appears to have limited utility in this setting. These findings support a treatment-specific, time-dependent approach to biomarker-based risk stratification in immunotherapy.
Förderung
- This study did not receive any financial support from public, commercial, or non-profit funding agencies.
Zitieren
APA
Doğan, T., Taş, S., Kantar, T. G., İspir, E., Hafızoğlu, E., Özdemir, M., Bir, F., Taşköylü, B. Y., Demiray, A. G., Yaren, A., & Dogu, G. G. (2026). On-treatment dNLR and metastatic burden predict survival in advanced non-small-cell lung cancer treated with nivolumab. Turkish Journal of Clinics and Laboratory. https://doi.org/10.18663/tjcl.1849630
Vancouver
Doğan T, Taş S, Kantar TG, İspir E, Hafızoğlu E, Özdemir M, et al. On-treatment dNLR and metastatic burden predict survival in advanced non-small-cell lung cancer treated with nivolumab. Turkish Journal of Clinics and Laboratory. 2026. doi:10.18663/tjcl.1849630
BibTeX
@article{Doan2026,
author = {Doğan, Tolga and Taş, Semra and Kantar, Taliha Güçlü and İspir, Emre and Hafızoğlu, Emre and Özdemir, Melek and Bir, Ferda and Taşköylü, Burcu Yapar and Demiray, Atike Gökçen and Yaren, Arzu and Dogu, Gamze Gokoz},
title = {On-treatment dNLR and metastatic burden predict survival in advanced non-small-cell lung cancer treated with nivolumab},
journal = {Turkish Journal of Clinics and Laboratory},
year = {2026},
number = {1},
doi = {10.18663/tjcl.1849630}
}
EUVIMED